Molecular mechanisms of novel therapeutic approaches for multiple myeloma

Nature Reviews Cancer

Volumn 2, Issue 12, 2002, Pages 927-937

  Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AE 941; ANSAMYCIN DERIVATIVE; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; LONAFARNIB; OSTEOPROTEGERIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VATALANIB; VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; BONE MARROW; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNOMODULATION; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TUMOR GROWTH; APOPTOSIS; BONE DISEASE; DNA MICROARRAY; DRUG EFFECT; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DISEASES; ENZYME INHIBITORS; HUMANS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 0036884062     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc952     Document Type: Review

References (140)

1. Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nature Rev. Cancer 2, 175-187 (2002). A comprehensive current review of the molecular pathogenesis of myeloma.
2. Anderson, K. C. Targeted therapy for multiple myeloma. Semin. Hematol. 38, 286-297 (2001).
3. Gregory W. M., Richards, M. A. & Malpas, J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol. 10, 334-342 (1992).
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. 16, 3832-3842 (1998).
5. Attal, M. & Harousseau, J. L. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin. Hematol. 38, 228-230 (2001). Reviews the evidence that high-dose therapy and stem-cell transplant achieves an improved patient outcome when compared with conventional therapy.
6. Fermand, J. P. et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front of rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92, 3131-3136 (1998).
7. Lenhoff, S. et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95, 7-11 (2000).
8. Desikan, R. et al. Results of high-dose therapy for 1,000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95, 4008-4010 (2000).
9. Fermand, J. P. et al. Single versus tandem high-dose therapy supported with autologous stem cell transplantation using unseleted of CD 34 enriched ABSC: preliminary results of a two by two designed randomized trial. Blood 98, 815a (2001).
10. Attal, M. et al. Single versus double transplant in myeloma: A randomized trial of the Inter Groupe Francais du Myelome (IFM). Blood (in the press).
11. Massaia, M. et al. Idotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673-683 (1999)
12. Gahrton, G. et al. Allogeneic bone marrow transplantation in multiple myeloma. N. Engl. J. Med. 325, 1267-1273 (1991).
13. Gahrton, G. et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow centers. Br. J. Haematol. 113, 209-216 (2001).
14. Alyea, E. et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934-939 (2001).
15. Badros, A. et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97, 2574-2579 (2001).
16. Kroger, N. et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100, 755-760 (2002).
17. Rajkumar, S. V., Gertz, M. A., Kyle, R. A. & Greipp, P. R. Current therapy for multiple myeloma. Mayo. Clin. Proc. 77, 813-822 (2002).
18. Berenson, J. R. et al. American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 20, 3719-3736 (2002).
19. Salmon, S. E., et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78, 44-50 (1991).
20. Sonneveld, P., Schoester, M. & de Leeuw, K. Clinical modulation of multidrug resistance in multiple myeloma: effects of cyclosporine on resistant tumor cells. J. Clin. Oncol. 12, 1584-1591 (1994).
21. Grogan, T. et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81, 490-495 (1993).
22. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002).
23. Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999). The first report showing that thalidomide can achieve clinical benefit in patients with myeloma that is refractory to conventional therapy.
24. Barlogie, B. et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase II study of 169 patients. Blood 98, 492-494 (2001).
25. D'Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085 (1994). The first report demonstrating the anti-angiogenic activity of thalidomide.
26. Bakkus, M. H. C. et al. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80, 2326-2335 (1992).
27. Vescio, R. A. et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J. Immunol. 155, 2487-2497 (1995).
28. Facon, T. et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97, 1566-1571 (2001).
29. Sawyer, J. R. et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br. J. Haematol, 112, 167-174 (2001).
30. Bergsagel, P. L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl Acad. Sci. USA 93, 13931-13936 (1996). The first demonstration of a common site of translocations in myeloma.
31. Fonseca, R. et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99, 3735-3741 (2002).
32. Tricot, G. et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br. J. Haematol. 1161 211-217 (2002).
33. Teoh, G. & Anderson, K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 11, 27-42 (1997).
34. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R. & Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. 162, 248-255 (1995).
35. Chauhan, D. et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89, 227-234 (1997).
36. Ogata, A. et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 159, 2212-2221 (1997).
37. Tu, Y., Gardner, A. & Lichtenstein, A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 60, 6763-6770 (2000).
38. Hideshima, T., Nakamura, N., Chauhan, D. & Anderson, K. C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20, 5991-6000 (2001).
39. Freund, G. G., Kulas, D. T. & Mooney, R. A. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J. Immunol. 151, 1811-1820 (1993).
40. Ogawa, M. et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 60, 4262-4269 (2000).
41. Mitsiades, C. S. et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21, 5673-5683 (2002).
42. Brenne, A. T. et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99, 3756-3762 (2002).
43. Podar, K. et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98, 428-435 (2001). The first report showing that VEGF can induce the migration of human MM cells.
44. Podar, K. et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with β1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα activation. J. Biol. Chem. 277, 7875-7881 (2002).
45. Hideshima, T. et al. The biologic sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol. Cancer Ther. 1, 539-544 (2002).
46. Uchyama, H., Barut, B. A., Mohrbacher, A. F., Chauhan, D. & Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82, 3712-3720 (1993).
47. Chauhan, D. et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 87, 1104-1112 (1996). This study showed that paracrine cytokine production in MM BM is NF-κB dependent.
48. Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630-2636 (2000).
49. Gupta, D. et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15, 1950-1961 (2001).
50. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P. & Anderson, K. C. The role of tumor necrosis factor α in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene 20, 4519-4527 (2001).
51. Ge, N. L. & Rudikoff, S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96, 2856-2861 (2000).
52. Ferlin, M. et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br. J. Haematol. 111, 626-634 (2000).
53. Qiang, Y. W., Kopantzev, E. & Rudikoff, S. Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99, 4138-4146 (2002).
54. Sonneveld, P. in VI International Workshop on Multiple Myeloma (Boston, 1997).
55. Covelli, A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann. Oncol. 10, 53-59 (1999).
56. Schwarzenbach, H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med. Oncol. 19, 87-104 (2002).
57. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999). Shows that adherence of MM cells to fibronectin confers resistance to conventional chemotherapy.
58. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319-4327 (2000).
59. Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795-804 (2001).
60. Mitsiades, N. et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99, 4525-4530 (2002).
61. Chauhan, D. et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem. 275, 27845-27850 (2000).
62. Hayashi, T. et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther. 1, 851-860 (2002).
63. Mitsiades, N. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374-14379 (2002). Demonstrates the transcriptional changes induced in MM cells after PS-341 treatment.
64. Chauhan, D. et al. RAFTK/PYK2-dependent and- independent apoptosis in multiple myeloma cells. Oncogene 18, 6733-6740 (1999).
65. Chauhan, D. et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 276, 24453-24456 (2001).
66. Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115 (1999).
67. Dalton, W. S. & Jove, R. Drug resistance in multiple myeloma: approaches to circumvention. Semin. Oncol. 26, 23-27 (1999).
68. Puthier, D. Bataille, R. & Amiot, M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. 29, 3945-3950 (1999).
69. Wei, L. H. et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20, 5799-5809 (2001).
70. Epling-Burnette, P. K. et al. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J. Immunol. 166, 7486-7495 (2001).
71. Mitsiades, N. et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications Blood 99, 4079-4086 (2002).
72. Hideshima, T. et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647 (2002). Defines the selective impact of inhibiting activation of NF-κB in myeloma.
73. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A. & Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J. Exp. Med. 173, 699-703 (1991).
74. Moreira, A. L. et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680 (1993).
75. Sampaio, E. P. et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168, 408-414 (1993).
76. Kenyon, B. M., Browne, F. & D'Amato, R. J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye. Res. 64, 971-978 (1997).
77. Kotoh, T. et al. Anti-angiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 125, 536-544 (1999).
78. Ribatti, D. et al. Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Res. 21, 4333-4339 (2001).
79. Vacca, A. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073 (1999).
80. Stirling, D. Thalidomide: a novel template for anticancer drugs. Semin. Oncol. 28, 602-606 (2001).
81. Hideshima, T. et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96, 2943-2950 (2000). The first study to define molecular mechanisms by which these drugs mediate anti-MM activity.
82. Davies, F. E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216 (2001).
83. Lentzsch, S. et al. S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 62, 2300-2305 (2002).
84. Richardson, P. et al. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100, 3063-3067 (2002). The first report to show that IMiDs achieve responses in patients whose myeloma is refractory to conventional therapies.
85. King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652-1959 (1996).
86. Kisselv, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 21, 1-20 (2001).
87. Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
88. Orkowski, R. Z. et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58, 4342-4348 (1998).
89. Tan, C. & Waldmann, T. A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 62, 1083-1086 (2002).
90. Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638-2645 (1999).
91. Harbison, M. T. et al. Proteasome inhibitor PS-341 is effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-κB and subsequent inhibition of vascular endothelial growth factor production. Proc. Am. Assoc. Cancer Res. 41, 71a (2000).
92. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res. 61, 3071-3076 (2001). The first Report to define the molecular mechanisms by which the proteasome inhibitor PS-341 mediates anti-MM activity.
93. Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (in the press).
94. Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (in the press).
95. LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
96. Richardson, P. G. et al. Phase II trial of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 98, 774a (2001). This is the first phase II study to show that PS-341 can achieve responses in patients whose MM is refractory to conventional therapies.
97. Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst. 90, 124-133 (1998).
98. Rousselot, P. et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients Cancer Res. 59, 1041-1048 (1999).
99. Park, W. H. et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60, 3065-3071 (2000).
100. 3) on myeloma cells. Leuk. Res. 25, 227-325 (2001).
101. Hussein, M. A. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med. Oncol. 16, 239-242 (2001).
102. Grad, J. M. et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98, 805-813 (2001).
103. Bellamy, W. T., Richter, L., Frutiger, Y. & Grogan, T. M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59, 728-733 (1999).
104. Lin, B. et al. The vascular endothelial growth factor receptor kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62, 5019-5026 (2002).
105. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C. & Treon, S. P. Intracellular regulation of tumor necrosis factor-related apoptosis - inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99, 2162-2171 (2002).
106. Keifer, J. A. Guttridge, D. C. Ashburner, B. P. & Baldwin, A. S., Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem 276, 22382-22387 (2001).
107. Kapahi, P. et al. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J. Biol. Chem. 275, 36062-36066 (2000).
108. D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J. & Hamet, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl Acad Sci. USA 91, 3964-3968 (1994).
109. Klauber, N., Parangi, S., Flynn, E., Hamel, E. & D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57, 81-86 (1997).
110. Chauhan, D. et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma (MM) cells using oligonucleotide array. Blood (in the press).
111. Chauhan, D. et al. 2-Methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma. Blood 100, 2187-2194 (2002).
112. Falardeau, P., Champagne, P., Poyet, P., Hariton, C. & Dupont, E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28, 620-625 (2001).
113. Beliveau, R. et al. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin. Cancer Res. 8, 1242-1250 (2002).
114. Kato, K. et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl Acad. Sci. USA 89, 6403-6407 (1992).
115. Karp, J. E. et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 13, 470-476 (2001).
116. Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C. & Kaufmann, S. H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. 7, 1438-1445 (2001).
117. Karp, J. E. et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97, 3361-3369 (2001).
118. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C. & Treon, S. P. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell lines and patient tumor cells. Blood 98, 376a (2001).
119. Mitsiades, C. S. et al. The HSP90 molecular cheperone as a novel therapeutic target in hematologic malignancies. Blood 98, 377a (2001).
120. Kyle, R. A. Multiple myeloma: review of 869 cases. Mayo. Clin. Proc. 50, 29-40 (1975).
121. Garrett, I. R., et al. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 317, 526-532 (1987).
122. Cozzolino, F., et al. Production of interleukin-1 by bone marrow myeloma cells: its role in the pathogenesis of lytic bone lesions. Blood 74, 380-387 (1989).
123. Barille, S., Bataille, R., Rapp, M. J., Harousseau, J. L. & Amiot, M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J. Immunol. 163, 5723-5728 (1999).
124. Hjertner, O. et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94, 3883-3888 (1999).
125. Lacy, M. Q. et al. Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93, 300-305 (1999).
126. Zeimer, H. et al. Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma J. Pathol. 192, 336-341 (2000).
127. Han, J. H. et al. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 97, 3349-3353 (2001).
128. Choi, S. J. et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96, 671-675 (2000).
129. Seidel, C. et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388-392 (2000).
130. Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M. & Barille, S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98, 3527-3533 (2001).
131. Pearse, R. N. et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98, 11581-11586 (2001).
132. Standal, T. et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100, 3002-3007 (2002).
133. Lahtinen, R. et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340, 1049-1052 (1992).
134. Berenson, J. R. et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334, 488-493 (1996).
135. Major, P. et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19, 558-567 (2001).
136. Derenne, S. et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. 14, 2048-2056 (1999).
137. Yaccoby, S., Barlogie, B. & Epstein, J. Primary myeloma cells growting in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908-2913 (1998).
138. Oyajobi, B. O. et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61, 2572-2578 (2001).
139. Mauro, M. J., O'Dwyer, M., Heinrich, M. C. & Druker, B. J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20, 325-334 (2002).
140. Jing, Y., Xia, L. & Waxman, S. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 100, 1008-1013 (2002).